MCID: FLR002
MIFTS: 55

Filariasis

Categories: Infectious diseases, Rare diseases

Aliases & Classifications for Filariasis

MalaCards integrated aliases for Filariasis:

Name: Filariasis 12 74 58 54 15 71 32
Disease Due to Superfamily Filarioidea 12

Characteristics:

Orphanet epidemiological data:

58
filariasis
Inheritance: Not applicable; Prevalence: >1/1000; Age of onset: All ages;

Classifications:

Orphanet: 58  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:1080
ICD9CM 34 125.9
NCIt 49 C34611
SNOMED-CT 67 105706003
MESH via Orphanet 44 D005368
ICD10 via Orphanet 33 B74.0 B74.1 B74.2 more
UMLS via Orphanet 72 C0016085
Orphanet 58 ORPHA2034
UMLS 71 C0016085

Summaries for Filariasis

Disease Ontology : 12 A parasitic helminthiasis infectious disease that involves parasitic infection of the lymphatics and subcutaneous tissue by nematodes of the superfamily Filarioidea.

MalaCards based summary : Filariasis, also known as disease due to superfamily filarioidea, is related to filarial elephantiasis and onchocerciasis. An important gene associated with Filariasis is IL5 (Interleukin 5), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Diethylcarbamazine and Doxycycline have been mentioned in the context of this disorder. Affiliated tissues include testes, breast and skin, and related phenotypes are immune system and digestive/alimentary

Wikipedia : 74 Filariasis is a parasitic disease caused by an infection with roundworms of the Filarioidea type. These... more...

Related Diseases for Filariasis

Diseases related to Filariasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 826)
# Related Disease Score Top Affiliating Genes
1 filarial elephantiasis 34.8 TLR4 TLR2 IL5 IL10
2 onchocerciasis 32.7 LGALS3BP IL5 IL2 IGHE CCL5
3 volvulus of midgut 31.7 TLR2 CRP ALB
4 lymphangitis 31.5 FLT4 CRP ALB
5 eosinophilic pneumonia 31.4 IL6 IL5 CCL5
6 hypereosinophilic syndrome 31.2 IL5 IL2 IL10 IGHE IFNG CCL5
7 endomyocardial fibrosis 31.1 TNF IL5 IL10
8 ascaris lumbricoides infection 31.0 IL6 IL5 IL10 IFNG
9 lymphadenitis 31.0 TNF TLR4 IL10 IFNG CRP
10 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 31.0 IL10 IFNG CTLA4
11 strongyloidiasis 30.8 LGALS3BP IL5 IGHE IFNG
12 encephalitis 30.8 TNF TLR2 IL6 IL10 CCL5
13 orchitis 30.7 TNF IL6 IL2 IL10 CRP
14 cysticercosis 30.7 TLR4 IL6 IL10 IGHE
15 parasitic helminthiasis infectious disease 30.7 TNF TLR4 TLR2 IL6 IL5 IL2
16 trachoma 30.6 TNF IL6 IL10
17 yellow fever 30.6 IL6 IL5 CRP CCL5
18 chikungunya 30.6 TNF IL6 CCL5
19 toxocariasis 30.6 IL5 IL10 IGHE CRP
20 poliomyelitis 30.6 TNF IL10 IFNG
21 lymphangioma 30.6 IL6 IFNG FLT4
22 taeniasis 30.6 TNF TLR4 IL10 ALB
23 severe combined immunodeficiency 30.6 IL6 IL5 IL2 IL10 IFNG
24 trichomoniasis 30.5 TNF IL6 IL2
25 ige responsiveness, atopic 30.4 IL5 IL10 IGHE IFNG
26 pericardial effusion 30.4 IL6 CRP ALB
27 mastitis 30.4 TLR2 IL6 CCL5 ALB
28 fascioliasis 30.4 IL10 IFNG ALB
29 amebiasis 30.3 TNF TLR4 TLR2 ALB
30 rheumatic heart disease 30.3 TNF TLR2 IL6 IL10
31 keratitis, hereditary 30.3 TNF TLR4 TLR2 IL6
32 schistosomiasis 30.3 TNF IL5 IL2 IL10 IGHE IFNG
33 protein-energy malnutrition 30.3 TNF IL6 ALB
34 tracheitis 30.3 TNF IL6 CRP
35 arthropathy 30.3 TNF IL6 IFNG CRP
36 tenosynovitis 30.3 TNF IL6 CRP
37 iritis 30.3 TNF IL6 CRP
38 urinary schistosomiasis 30.3 IL5 IL10 IGHE IFNG CTLA4
39 systemic autoimmune disease 30.3 IL6 CRP
40 pulmonary hypertension 30.3 TNF IL6 IL10 CRP ALB
41 thrombophlebitis 30.2 TNF CRP ALB
42 b cell deficiency 30.2 TNF IL6 IL2 IL10 CTLA4
43 iridocyclitis 30.2 TNF IL6 IL10 CRP
44 mucocutaneous leishmaniasis 30.2 TNF IL5 IL2 IL10 IFNG
45 amyloidosis 30.2 TNF IL6 CRP ALB
46 panuveitis 30.2 TNF IL6 IL10 CRP
47 lepromatous leprosy 30.2 TNF TLR2 IL2 IL10 IFNG
48 uveitis 30.2 TNF IL6 IL2 IL10 IFNG CTLA4
49 retinal detachment 30.2 TNF IL6 IL10 IFNG
50 necrotizing fasciitis 30.1 IL6 IL2 CRP ALB

Graphical network of the top 20 diseases related to Filariasis:



Diseases related to Filariasis

Symptoms & Phenotypes for Filariasis

MGI Mouse Phenotypes related to Filariasis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 10.3 ALB CCL5 CHIT1 CRP CTLA4 FLT4
2 digestive/alimentary MP:0005381 10.25 ALB CTLA4 FLT4 FOXC2 IFNG IL10
3 homeostasis/metabolism MP:0005376 10.24 ALB CRP CTLA4 FLT4 FOXC2 IFNG
4 cardiovascular system MP:0005385 10.23 ALB CRP CTLA4 FLT4 FOXC2 IFNG
5 hematopoietic system MP:0005397 10.22 CCL5 CTLA4 IFNG IL10 IL2 IL5
6 liver/biliary system MP:0005370 10.03 ALB CTLA4 FLT4 FOXC2 IFNG IL10
7 muscle MP:0005369 9.81 ALB FLT4 FOXC2 IFNG IL10 IL6
8 neoplasm MP:0002006 9.61 ALB IFNG IL10 IL2 IL5 IL6
9 respiratory system MP:0005388 9.32 CTLA4 FOXC2 IFNG IL10 IL2 IL5

Drugs & Therapeutics for Filariasis

Drugs for Filariasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 32)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Diethylcarbamazine Approved, Investigational, Vet_approved Phase 4 90-89-1 3052
2
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
3 Antimalarials Phase 4
4 Vitamins Phase 3
5 Milbemycin Phase 3
6
Reslizumab Approved, Investigational Phase 2 241473-69-8
7
Dihydroartemisinin Experimental, Investigational Phase 2 71939-50-9 6918483
8
Piperaquine Experimental, Investigational Phase 2 4085-31-8 5079497
9 Respiratory System Agents Phase 2
10 Immunoglobulins Phase 2
11 Antibodies Phase 2
12 Anti-Asthmatic Agents Phase 2
13 Antibodies, Monoclonal Phase 2
14 Protein Kinase Inhibitors Phase 2
15 Imatinib Mesylate Phase 2 220127-57-1 123596
16
Romidepsin Approved, Investigational Phase 1 128517-07-7 5352062
17
Emodepside Investigational, Vet_approved Phase 1 155030-63-0
18 Pharmaceutical Solutions Phase 1
19 Toltrazuril Phase 1
20
Polidocanol Approved 9002-92-0
21
Sodium citrate Approved, Investigational 68-04-2
22
Mebendazole Approved, Vet_approved 31431-39-7 4030
23
Piperazine Approved, Vet_approved 110-85-0 4837
24
Permethrin Approved, Investigational 52645-53-1 40326
25
Citric acid Approved, Nutraceutical, Vet_approved 77-92-9 311
26 Anesthetics
27 Sclerosing Solutions
28 Citrate
29 Piperazine citrate
30 DMP 777 157341-41-8
31 Liver Extracts
32 Insect Repellents

Interventional clinical trials:

(show top 50) (show all 62)
# Name Status NCT ID Phase Drugs
1 Impact of Albendazole -Ivermectin Combination Treatment on Wuchereria Bancrofti Infection and Transmission in Mali Completed NCT02784743 Phase 4 ''albendazole'' and ''ivermectin''
2 Cluster Randomized Community-based Trial of Annual Versus Biannual Single-dose Ivermectin Plus Albendazole Against Wuchereria Bancrofti Infection in Human and Mosquito Populations Completed NCT03036059 Phase 4 400 μg/kg Ivermectin + 400 mg Albendazole
3 Alternate Chemotherapy Regimens for the Clearance of W.Bancrofti Infection: Double Blind Randomised Clinical Trial (RCT) to Study the Efficacy of Different Co-administration and Sequential Administration Completed NCT02005653 Phase 4 Diethylcarbamazine;Albendazole;Doxycycline
4 Comparison Between the Post-Treatment Reactions After Single-dose Ivermectin or DEC in Subjects With Loa Loa Infection Completed NCT01593722 Phase 4 Diethylcarbamazine;Ivermectin
5 Safety of the Co-administration of Azithromycin, Albendazole and Ivermectin Versus Standard Treatment Regimens During Mass Drug Administration (MDA) in Ethiopia: a Cluster-randomized Trial Not yet recruiting NCT03570814 Phase 4 Administration of Albendazole on Day 1;Administration of Ivermectin on Day 1;Administration of Azithromycin on Day 1;Administration of Azithromycin on Day 15
6 AZIVAL 2: A Double-blind Cluster-randomized Placebo-controlled Study on the Safety of Integrated Treatment of Trachoma and Lymphatic Filariasis in Children and Adults With Azithromycin, Ivermectin and Albendazole Withdrawn NCT01903057 Phase 4 azithromycin;ivermectin;albendazole;placebo
7 Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in Subjects With Schistosomiasis: A Pilot Study Withdrawn NCT02734186 Phase 4 Praziquantel
8 Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study Completed NCT02509481 Phase 2, Phase 3 Ivermectin;Albendazole
9 A Cluster Randomised Trial of the Safety of Co-Administration of IDA (Ivermectin, Diethylcarbamazine and Albendazole) & Azithromycin for Integrated Treatment of Neglected Tropical Diseases Completed NCT03676140 Phase 3 Albendazole on Day 1;Ivermectin on Day 1;Diethylcarbamazine on day 1;Azithromycin on Day 1;Azithromycin on Day 8
10 Comparison of Ivermectin Alone With Albendazole (ALB) Plus Ivermectin (IVM) in Their Efficacy Against Onchocerciasis Completed NCT03238131 Phase 3 Ivermectin;Albendazole
11 Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH) Recruiting NCT03014167 Phase 3 Albendazole
12 A Clinical Trial to Assess the Safety and Efficacy of Moxidectin Combination Treatments vs. Ivermectin Combination Treatments for Bancroftian Filariasis Recruiting NCT04410406 Phase 3 IA (IVM+ ABZ);MoxA (Mox + ABZ);IDA (IVM + DEC + ABZ);MoxDA (Mox + DEC + ABZ)
13 A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection Active, not recruiting NCT02929134 Phase 3 Doxycycline;Placebo
14 A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection Active, not recruiting NCT02929121 Phase 3 Doxycycline;Placebo
15 A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection Active, not recruiting NCT02927496 Phase 3 Doxycycline;Placebo
16 Evaluate Triple-Drug Therapy With Diethylcarbamize (DEC), Albendazole (ALB) and Ivermectin (IVM) That Could Accelerate LF Elimination Outside of Africa Completed NCT01975441 Phase 2 Diethylcarbamazine;Albendazole;Ivermectin
17 Effect of Albendazole Dose and Interval on Brugia Malayi Microfilarial Clearance in India: A Randomized, Open Label Study Completed NCT00511004 Phase 2 Albendazole;Diethylcarbamazine
18 Effect of Albendazole and Ivermectin Dose on Wuchereria Bancrofti Microfilarial Clearance in Mali: A Randomized, Open Label Study Completed NCT00339417 Phase 2 Albendazole;Ivermectin
19 A Pharmacokinetic and Pharmacodynamic Evaluation of Co-Administration of IDA (Ivermectin, Diethylcarbamazine and Albendazole) & Azithromycin for Integrated Treatment of Neglected Tropical Diseases Completed NCT03664063 Phase 2 Azithromycin;Albendazole;Ivermectin;Diethylcarbamazine
20 Effect of Albendazole Dose and Interval on Wuchereria Bancrofti Microfilarial Clearance in India: A Randomized, Open Label Study Completed NCT00375583 Phase 2 DEC/Albendazole
21 Treatment of Mansonella Perstans Infection in an Area Coendemic for Lymphatic Filariasis: A Pilot Study of the Effects of Doxycycline Completed NCT00340691 Phase 2 Doxycycline
22 Efficacy and Safety of High-dose Ivermectin for Reducing Malaria Transmission: A Dose Finding Study (IVERMAL) Completed NCT02511353 Phase 2 ivermectin;placebo;dihydroartemisinin-piperaquine
23 A Randomized, Placebo-controlled, Double-Blind Pilot Study of Single-Dose Humanized Anti-IL5 Antibody (Reslizumab) for the Reduction of Eosinophilia Following Diethylcarbamazine Treatment of Loa Loa Infection Completed NCT01111305 Phase 2 Reslizumab;Diethylcarbamazine
24 A Pilot, Proof of Concept Trial to Prove Ivermectin Efficacy in the Reduction of SARS-CoV-2 Replication at Early Stages of COVID-19 Recruiting NCT04381884 Phase 2 IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care.
25 A Double-Blinded, Randomized, Placebo-Controlled Dose Escalation Study to Examine the Microfilaricidal Kinetics and Safety of Imatinib for the Treatment of Loa Loa (A Pilot Study) Active, not recruiting NCT02644525 Phase 2 Imatinib Mesylate;Placebo
26 Safety and Efficacy of Combination Therapy With Ivermectin, Diethylcarbamazine, and Albendazole (IDA) for Individuals With Onchocerciasis Enrolling by invitation NCT04188301 Phase 2 IVM w/ ALB;Single dose of IDA;Three daily doses of IDA
27 Multicenter, Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of Ivermectin in Mild Virus-positive Subjects (SARS-CoV)-2 With or Without Symptoms Not yet recruiting NCT04407507 Phase 2 Ivermectin;Placebo
28 A Phase 1, Single-Blind, Randomized, Placebo Controlled, Parallel-Group, Multiple-Dose-Escalation Study to Investigate Safety, Tolerability, and Pharmacokinetics of Emodepside (BAY 44-4400) After Oral Dosing in Healthy Male Subjects Completed NCT03383614 Phase 1 LSF emodepside (BAY 44-4400) or matching placebo
29 A Phase 1, Blinded, Randomized, Placebo Controlled, Parallel-Group, Single-Dose, Dose-Escalation Study to Investigate Safety, Tolerability, and Pharmacokinetics of Emodepside (BAY 44-4400) After Oral Dosing in Healthy Male Subjects Completed NCT02661178 Phase 1 emodepside (BAY 44-4400);placebo
30 Phase1,Randomized,Open-Label,Parallel-Group,Relative Bioavailability Study to Investigate PK,Including Food Effect,Safety and Tolerability of Single Doses of New Immediate Release Tablet Formulations of Emodepside (BAY 44-4400),Compared to Oral Solution,in Healthy Male Subjects Completed NCT03383523 Phase 1 Emodepside (BAY 44-4400)
31 Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single Dose Treatment With Diethylcarbamazine, Albendazole and Ivermectin in Humans With and Without Wuchereria Bancrofti Infection in Côte d'Ivoire Completed NCT02845713 Phase 1 Ivermectin, Diethylcarbamazine Albendazole (IDA)
32 Lord´s Procedure Versus Sclerotherapy for Testicular Hydrocele; a Randomized Controlled Study. Unknown status NCT02082613
33 Exhaled NO Testing in Filariasis Completed NCT01628497
34 Research for Elimination of Lymphatic Filariasis (ICIDR) Completed NCT00406627
35 Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India Completed NCT01629771
36 Research for Elimination of Human Filariasis Completed NCT00145223
37 A Pharmacovigilance Study on the Safety of Integrated Treatment of Trachoma and Lymphatic Filariasis in Children and Adults Living in the Sikasso Region of Mali Completed NCT01586169 triple co administration at once of the combination of Albendazole + ivermectin + azithromycin
38 Studies on the Interaction Between HIV Infection, Lymphatic Filariasis and Diethylcarbamazine Completed NCT00295698 Diethylcarbamazine
39 Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) Versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis Completed NCT02899936 3 drug dose - IDA;2 drug dose - DA
40 Community Studies to Monitor the Impact of Triple Drug Therapy Relative to Double Drug Therapy on Lymphatic Filariasis Infection Indicators Completed NCT03352206 2 drug dose - DA;3 drug dose - IDA
41 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis Completed NCT01905423 Albendazole and diethylcarbamazine
42 Coinfection With Plasmodium Falciparum and Wuchereria Bancrofti: Clinical, Epidemiologic and Immunologic Implications Completed NCT00471666
43 Evaluation of Antibacterial Soap for Treatment of Lymphedema and Elephantiasis in an Area Endemic for Lymphatic Filariasis Completed NCT00139100 antimicrobial agent in soap
44 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast Completed NCT02032043 Annual versus Semiannual Albendazole plus Ivermectin MDA
45 Changes in HIV Viral Load in Patients Undergoing Treatment for Filarial Infection Completed NCT00344279
46 Gaps in Helminth Control: Safety and Efficacy of Drug Combinations Against Triple Infections Completed NCT01050517 albendazole + ivermectin + praziquantel;albendazole + ivermectin + (1 week later) praziquantel
47 Regulation of Innate and Adaptive Immune Responses in Individuals Infected Concurrently With Malarial and Filarial Parasites Completed NCT00341666
48 Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) Versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji Completed NCT03177993 3 drug dose - IDA;3 drug dose - IDA with second dose of ivermectin;2 drug dose - DA
49 Alternative Chemotherapies for Lymphatic Filariasis (LF) Treatment and Elimination in Africa [Cote d'Ivoire] Completed NCT02974049 Albendazole;Ivermectin;Diethylcarbamazine
50 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis: Monitoring Efficacy of Ongoing Treatment Programs in Papua New Guinea Completed NCT03268252

Search NIH Clinical Center for Filariasis

Genetic Tests for Filariasis

Anatomical Context for Filariasis

MalaCards organs/tissues related to Filariasis:

40
Testes, Breast, Skin, T Cells, Lung, Liver, Lymph Node

Publications for Filariasis

Articles related to Filariasis:

(show top 50) (show all 6392)
# Title Authors PMID Year
1
Protective immunity in human filariasis: a role for parasite-specific IgA responses. 54 61
18588480 2008
2
Chitotriosidase deficiency is not associated with human hookworm infection in a Papua New Guinean population. 61 54
17765019 2007
3
IgE memory: persistence of antigen-specific IgE responses years after treatment of human filarial infections. 61 54
16630955 2006
4
Interleukin-10 (IL-10) counterregulates IL-4-dependent effector mechanisms in Murine Filariasis. 54 61
15501755 2004
5
Polymorphisms of innate immunity genes and susceptibility to lymphatic filariasis. 61 54
14551607 2003
6
A four year follow up study of filaria specific IgE response in individuals with hydrocele. 54 61
11247197 2000
7
IL-5 is essential for vaccine-induced protection and for resolution of primary infection in murine filariasis. 61 54
11138639 2000
8
Antigen-stimulated IL-4, IL-13 and IFN-gamma production by human T cells at a single-cell level. 61 54
9808184 1998
9
Differential decline in filaria-specific IgG1, IgG4, and IgE antibodies in Brugia malayi-infected patients after diethylcarbamazine chemotherapy. 61 54
7594718 1995
10
Differential antibody isotype reactivity to specific antigens in human lymphatic filariasis: gp15/400 preferentially induces immunoglobulin E (IgE), IgG4, and IgG2. 54 61
7558279 1995
11
Differential expression of IgE and IgG4 specific antibody responses in asymptomatic and chronic human filariasis. 61 54
8473742 1993
12
Cytokine regulation of antigen-driven immunoglobulin production in filarial parasite infections in humans. 54 61
2112154 1990
13
The immune response of inbred laboratory mice to Litomosoides sigmodontis: A route to discovery in myeloid cell biology. 61
32145033 2020
14
Microfilaria in urine cytology: Report of three cases with review of literature. 61
32259405 2020
15
Green synthesis of silver nanoparticles using Indian Belladonna extract and their potential antioxidant, anti-inflammatory, anticancer and larvicidal activities. 61
32300886 2020
16
Risk factors associated with failing pre-transmission assessment surveys (pre-TAS) in lymphatic filariasis elimination programs: Results of a multi-country analysis. 61
32479495 2020
17
Standardisation of lymphatic filariasis microfilaraemia prevalence estimates based on different diagnostic methods: a systematic review and meta-analysis. 61
32527335 2020
18
Post-Treatment Surveillance for Lymphatic Filariasis in Plateau and Nasarawa States, Nigeria: Results of Transmission Assessment Surveys. 61
32228796 2020
19
Nearly Complete Genome Sequence of Brugia malayi Strain FR3. 61
32527783 2020
20
The impact of four years of semiannual treatments with albendazole alone on lymphatic filariasis and soil-transmitted helminth infections: A community-based study in the Democratic Republic of the Congo. 61
32574160 2020
21
Safety and efficacy of co-administered diethylcarbamazine, albendazole and ivermectin during mass drug administration for lymphatic filariasis in Haiti: Results from a two-armed, open-label, cluster-randomized, community study. 61
32511226 2020
22
Pancytopenia: a rare cause for a common presentation. 61
32539585 2020
23
Design, expression, and evaluation of novel multiepitope chimeric antigen of Wuchereria bancrofti for the diagnosis of lymphatic filariasis - A structure-based strategy. 61
32222640 2020
24
When, Who, and How to Sample: Designing Practical Surveillance for 7 Neglected Tropical Diseases as We Approach Elimination. 61
32529261 2020
25
Design and Analysis of Elimination Surveys for Neglected Tropical Diseases. 61
31930383 2020
26
Designing antifilarial drug trials using clinical trial simulators. 61
32483209 2020
27
Massive microfilaremia in a dog subclinically infected with Acanthocheilonema dracunculoides. 61
32036036 2020
28
Immunolocalization of Disorganized Muscle Protein-1 in Different Life Stages of Human Lymphatic Filariid, Brugia malayi. 61
32500507 2020
29
Pediatric Allergic Diseases in the Indian Subcontinent -Epidemiology, Risk Factors and Current Challenges. 61
32521565 2020
30
Genetic and functional diversification of chemosensory pathway receptors in mosquito-borne filarial nematodes. 61
32511224 2020
31
The Health and Economic Burdens of Lymphatic Filariasis Prior to Mass Drug Administration Programs. 61
31343064 2020
32
Elimination or Resurgence: Modelling Lymphatic Filariasis After Reaching the 1% Microfilaremia Prevalence Threshold. 61
31853554 2020
33
An outbreak of acute skin and soft tissue infections including necrotizing fasciitis in Kalwala village, India, 2018: Public health implications for the lymphatic filariasis elimination program. 61
32562418 2020
34
Eliminating Lymphatic Filariasis: Is it Worth it? 61
31343066 2020
35
A systematic review of alternative surveillance approaches for lymphatic filariasis in low prevalence settings: Implications for post-validation settings. 61
32396575 2020
36
Review of MDA registers for Lymphatic Filariasis: Findings, and potential uses in addressing the endgame elimination challenges. 61
32407319 2020
37
Significant improvement in quality of life following surgery for hydrocoele caused by lymphatic filariasis in Malawi: A prospective cohort study. 61
32384094 2020
38
Prevalence and Correlates of Lymphatic Filariasis Infection and Its Morbidity Following Mass Ivermectin and Albendazole Administration in Mkinga District, North-Eastern Tanzania. 61
32455556 2020
39
The roles of stakeholder experience and organizational learning in declining mass drug administration coverage for lymphatic filariasis in Port-au-Prince, Haiti: A case study. 61
32469860 2020
40
Factors Influencing the Sustainability of Neglected Tropical Disease Elimination Programs: A Multi-Case Study of the Kenya National Program for Elimination of Lymphatic Filariasis. 61
32124717 2020
41
Notes from the Field: Impact of a Mass Drug Administration Campaign Using a Novel Three-Drug Regimen on Lymphatic Filariasis Antigenemia - American Samoa, 2019. 61
32463808 2020
42
Space occupying lesion of brain: An unusual site for a common infection. 61
32365273 2020
43
Hospitalization for Chagas disease, dengue, filariasis, leishmaniasis, schistosomiasis, strongyloidiasis, and Taenia solium taeniasis/cysticercosis, Italy, 2011-2016. 61
32418191 2020
44
Biological effects of Avicennia marina (Forssk.) vierh. extracts on physiological, biochemical, and antimicrobial activities against three challenging mosquito vectors and microbial pathogens. 61
32072409 2020
45
Antibody response to Schistosoma haematobium and other helminth species in malaria-exposed populations from Burkina Faso. 61
32007449 2020
46
Embryo Microinjection Techniques for Efficient Site-Specific Mutagenesis in Culex quinquefasciatus. 61
32510506 2020
47
Who Bites Me? A Tentative Discriminative Key to Diagnose Hematophagous Ectoparasites Biting Using Clinical Manifestations. 61
32429276 2020
48
Fecundity of adult female worms were affected when Brugia malayi infected Mongolian gerbils were immunized with a multivalent vaccine (rBmHAXT) against human lymphatic filarial parasite. 61
32437645 2020
49
Inhibition of Asaia in Adult Mosquitoes Causes Male-Specific Mortality and Diverse Transcriptome Changes. 61
32429180 2020
50
Essential oils from three Algerian medicinal plants (Artemisia campestris, Pulicaria arabica, and Saccocalyx satureioides) as new botanical insecticides? 61
32372353 2020

Variations for Filariasis

Expression for Filariasis

Search GEO for disease gene expression data for Filariasis.

Pathways for Filariasis

Pathways related to Filariasis according to GeneCards Suite gene sharing:

(show top 50) (show all 71)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.09 TNF TLR9 TLR6 TLR4 TLR2 TLR1
2
Show member pathways
13.73 TNF TLR4 IL6 IL5 IL2 IL10
3
Show member pathways
13.58 TNF IL6 IL5 IL2 IL10 IFNG
4
Show member pathways
13.47 TNF TLR9 TLR6 TLR4 TLR2 TLR1
5
Show member pathways
13.44 TNF IL6 IL5 IL2 IL10 IGHE
6
Show member pathways
13.35 TNF IL6 IL5 IL2 IL10 FLT4
7
Show member pathways
13.31 TNF TLR9 TLR6 TLR4 TLR2 TLR1
8
Show member pathways
13.12 TNF TLR9 TLR6 TLR4 TLR2 TLR1
9
Show member pathways
13.05 TNF TLR4 TLR2 IL6 IL2 FLT4
10
Show member pathways
12.96 TNF IL6 IL5 IL2 IL10 IFNG
11
Show member pathways
12.92 TNF TLR9 TLR4 TLR2 IL6 IL2
12 12.89 TNF TLR9 TLR2 IL6 IFNG CCL5
13
Show member pathways
12.84 TNF TLR9 TLR6 TLR4 TLR2 TLR1
14
Show member pathways
12.8 TNF TLR9 TLR6 TLR4 TLR2 TLR1
15
Show member pathways
12.72 TNF TLR4 TLR2 IL6 IL5 IL2
16
Show member pathways
12.7 TNF TLR9 TLR6 TLR4 TLR2 TLR1
17
Show member pathways
12.69 TNF IL2 IL10 IGHE IFNG
18
Show member pathways
12.66 TNF IL6 IL2 IL10 IFNG
19
Show member pathways
12.56 TNF TLR9 TLR4 TLR2 IL6 IL5
20
Show member pathways
12.53 TLR9 TLR6 TLR4 TLR2 TLR1 FLT4
21
Show member pathways
12.52 IL6 IL5 IL2 IL10 IFNG
22
Show member pathways
12.47 TNF IL6 IL2 IFNG CRP CCL5
23 12.47 TNF TLR9 TLR6 TLR2 TLR1 IL2
24
Show member pathways
12.45 TNF TLR2 IL6 IL5 IFNG
25
Show member pathways
12.44 TNF IL6 IL2 IL10 CCL5
26 12.43 TNF TLR9 TLR6 TLR4 TLR2 IL6
27
Show member pathways
12.38 TNF TLR4 TLR2 IL10 IFNG
28
Show member pathways
12.38 TNF IL6 IL5 IL2 IL10 IFNG
29
Show member pathways
12.38 TNF TLR9 TLR6 TLR4 TLR2 TLR1
30
Show member pathways
12.34 TNF TLR9 IL6 IL2 IL10
31 12.29 TNF TLR4 IL6 CCL5
32 12.25 TNF TLR9 TLR6 TLR4 TLR2 TLR1
33
Show member pathways
12.22 TNF TLR9 TLR6 TLR4 TLR2 TLR1
34 12.15 TNF IL6 IL5 IL2 IL10 IFNG
35
Show member pathways
12.15 TLR9 TLR6 TLR4 TLR2 TLR1 IL5
36 12.14 TNF TLR4 IL6 IL2 IL10
37 12.14 TNF TLR4 IL6 IL2 IFNG
38 12.08 TNF IL6 IL10 IGHE
39 12.07 TNF TLR4 TLR2 IL6 IL10 IFNG
40 11.99 TNF TLR4 TLR2 IL6 IFNG CTLA4
41 11.96 TLR9 TLR6 TLR4 TLR2 TLR1
42
Show member pathways
11.96 TLR9 TLR6 TLR4 TLR2 TLR1 IL6
43 11.92 IL6 IL5 IL2 IFNG
44 11.92 TNF IL5 IL2 IL10 IFNG
45
Show member pathways
11.9 TNF IL5 IL2 IFNG CTLA4
46 11.89 TNF TLR4 IL6 IL10
47 11.88 TNF TLR9 IL6 IL2 IL10 IFNG
48 11.86 TNF TLR9 TLR6 TLR4 TLR2 TLR1
49
Show member pathways
11.8 TNF IL6 IL2 IFNG
50 11.8 TNF IL6 IL5 CCL5

GO Terms for Filariasis

Cellular components related to Filariasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 TNF LGALS3BP IL6 IL5 IL2 IL10
2 extracellular region GO:0005576 9.47 TNF TLR9 LGALS3BP IL6 IL5 IL2
3 phagocytic vesicle membrane GO:0030670 9.43 TLR6 TLR2 TLR1
4 Toll-like receptor 1-Toll-like receptor 2 protein complex GO:0035354 9.16 TLR2 TLR1

Biological processes related to Filariasis according to GeneCards Suite gene sharing:

(show top 50) (show all 89)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.39 TLR9 TLR6 TLR4 TLR2 TLR1 LGALS3BP
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.31 TNF TLR9 TLR4 TLR2 IL6 IL2
3 immune system process GO:0002376 10.23 TLR9 TLR6 TLR4 TLR2 TLR1 IL2
4 innate immune response GO:0045087 10.21 TLR9 TLR6 TLR4 TLR2 TLR1 IGHE
5 positive regulation of gene expression GO:0010628 10.13 TNF TLR9 TLR6 TLR4 TLR2 IL6
6 defense response to bacterium GO:0042742 10.1 TNF TLR9 TLR6 TLR4 IL10 IGHE
7 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.06 TNF TLR4 FLT4 CCL5
8 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 10.05 TNF TLR9 TLR6 TLR4
9 positive regulation of protein phosphorylation GO:0001934 10.05 TNF IL2 IFNG FLT4
10 cellular response to lipopolysaccharide GO:0071222 10.05 TNF TLR4 IL6 IL10
11 cytokine-mediated signaling pathway GO:0019221 10.05 TNF IL6 IL5 IL2 IL10 IGHE
12 positive regulation of DNA-binding transcription factor activity GO:0051091 10.02 TNF IL6 IL5 IL10
13 defense response to Gram-positive bacterium GO:0050830 10.01 TNF TLR2 IL6 CRP
14 positive regulation of NF-kappaB transcription factor activity GO:0051092 10.01 TNF TLR9 TLR6 TLR4 TLR2 IL6
15 positive regulation of JNK cascade GO:0046330 9.98 TNF TLR9 TLR4 FLT4
16 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.96 TNF TLR9 TLR4 TLR2
17 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.95 TNF IL6 IL2 IFNG CCL5
18 regulation of insulin secretion GO:0050796 9.94 TNF IFNG CCL5
19 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.93 TNF TLR9 TLR4
20 response to glucocorticoid GO:0051384 9.93 TNF IL6 IL10
21 positive regulation of T cell proliferation GO:0042102 9.93 IL6 IL2 CCL5
22 positive regulation of smooth muscle cell proliferation GO:0048661 9.93 TNF IL6 CCL5
23 positive regulation of nitric oxide biosynthetic process GO:0045429 9.93 TNF TLR6 TLR4 IFNG
24 humoral immune response GO:0006959 9.92 TNF IL6 IFNG
25 positive regulation of tumor necrosis factor production GO:0032760 9.92 TLR9 TLR4 TLR2
26 positive regulation of interferon-gamma production GO:0032729 9.91 TNF TLR4 IL2
27 positive regulation of interleukin-6 secretion GO:2000778 9.91 TNF TLR4 TLR2 IFNG
28 positive regulation of B cell proliferation GO:0030890 9.91 TLR9 TLR4 IL5 IL2
29 positive regulation of JUN kinase activity GO:0043507 9.9 TNF TLR9 TLR6
30 negative regulation of interleukin-6 production GO:0032715 9.9 TNF TLR9 TLR4 IL10
31 positive regulation of cytokine secretion GO:0050715 9.89 TNF IL10 IFNG
32 positive regulation of interferon-beta production GO:0032728 9.89 TLR9 TLR4 TLR2
33 lipopolysaccharide-mediated signaling pathway GO:0031663 9.89 TNF TLR4 TLR2 CCL5
34 microglial cell activation GO:0001774 9.88 TNF TLR6 TLR2 IFNG
35 positive regulation of interleukin-8 production GO:0032757 9.88 TNF TLR9 TLR4 TLR2
36 positive regulation of interleukin-6 production GO:0032755 9.88 TNF TLR9 TLR4 TLR2 IL6
37 positive regulation of interleukin-10 production GO:0032733 9.87 TLR9 TLR4 TLR2
38 positive regulation of interleukin-12 production GO:0032735 9.87 TLR9 TLR4 TLR2 IFNG
39 positive regulation of tumor necrosis factor biosynthetic process GO:0042535 9.86 TLR4 TLR1 IFNG
40 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.86 TNF TLR6 TLR4 IL6
41 positive regulation of macrophage activation GO:0043032 9.85 TLR6 TLR4 IL10
42 regulation of regulatory T cell differentiation GO:0045589 9.85 IL2 IFNG CTLA4
43 positive regulation of interleukin-6 biosynthetic process GO:0045410 9.85 TNF TLR6 TLR1
44 positive regulation of inflammatory response GO:0050729 9.85 TNF TLR9 TLR4 TLR2 IL2 IFNG
45 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.84 TNF TLR9 TLR4
46 cell activation GO:0001775 9.83 TLR6 TLR2 TLR1
47 positive regulation of immunoglobulin secretion GO:0051024 9.83 IL6 IL5 IL2
48 I-kappaB phosphorylation GO:0007252 9.83 TLR9 TLR4 TLR2
49 toll-like receptor signaling pathway GO:0002224 9.83 TLR9 TLR6 TLR4 TLR2 TLR1
50 response to molecule of bacterial origin GO:0002237 9.82 TLR9 TLR2 IL10

Molecular functions related to Filariasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.41 TNF TLR9 TLR6 TLR4 TLR2 TLR1
2 identical protein binding GO:0042802 9.97 TNF TLR6 TLR4 TLR2 TLR1 FOXC2
3 growth factor activity GO:0008083 9.71 IL6 IL5 IL2 IL10
4 amyloid-beta binding GO:0001540 9.65 TLR6 TLR4 TLR2
5 NAD+ nucleotidase, cyclic ADP-ribose generating GO:0061809 9.46 TLR6 TLR4 TLR2 TLR1
6 lipopolysaccharide receptor activity GO:0001875 9.43 TLR4 TLR2
7 lipopeptide binding GO:0071723 9.43 TLR6 TLR2 TLR1
8 Toll-like receptor 2 binding GO:0035663 9.37 TLR6 TLR1
9 NAD(P)+ nucleosidase activity GO:0050135 9.26 TLR6 TLR4 TLR2 TLR1
10 cytokine activity GO:0005125 9.17 TNF IL6 IL5 IL2 IL10 IFNG

Sources for Filariasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....